Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Recipients of allogeneic hematopoietic stem cell transplant (HSCT) have been excluded from clinical trials of SARS-CoV-2 messenger RNA (mRNA) vaccines; however, since these patients are at higher risk of severe complications following infection, they have been given high priority in vaccination camp...

Descripción completa

Detalles Bibliográficos
Autores principales: Saraceni, Francesco, Fiorentini, Alessandro, Morè, Sonia, Guerzoni, Selene, Puglisi, Bruna, Corvaro, Benedetta, Caucci, Sara, Menzo, Stefano, Costantini, Andrea, Butini, Luca, Viola, Nadia, Scortechini, Ilaria, Mancini, Giorgia, Dubbini, Maria Vittoria, Federici, Irene, Kordasti, Shahram, Offidani, Massimo, Patriarca, Francesca, Battista, Marta Lisa, Chiarucci, Martina, Visani, Giuseppe, Falcioni, Sadia, Galieni, Piero, Natale, Annalisa, Vaddinelli, Doriana, Santarone, Stella, Colasante, Fabrizia, Carella, Angelo Michele, Battipaglia, Giorgia, Pane, Fabrizio, Olivieri, Attilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
722.Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701610/
http://dx.doi.org/10.1182/blood-2021-152907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701610/
http://dx.doi.org/10.1182/blood-2021-152907

Ejemplares similares